首页> 外文期刊>American Journal of Kidney Diseases: The official journal of the National Kidney Foundation >Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study.
【24h】

Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study.

机译:肾移植受者对流感疫苗接种的抗体应答降低:一项前瞻性队列研究。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Antibody response to the inactivated influenza vaccine is not well described in kidney transplant recipients administered newer, but commonly used, immunosuppression medications. We hypothesized that kidney transplant recipient participants administered tacrolimus-based regimens would have decreased antibody response compared with healthy controls. STUDY DESIGN: Prospective cohort study of 53 kidney transplant recipients and 106 healthy control participants during the 2006-2007 influenza season. All participants received standard inactivated influenza vaccine. SETTING & PARTICIPANTS: Kidney transplant recipients administered tacrolimus-based regimens at a single academic medical center and healthy controls. PREDICTOR: Presence of kidney transplant. OUTCOMES: Proportion of participants achieving seroresponse (4-fold increase in antibody titer) and seroprotection (antibody titer > or = 1:32) 1 month after vaccination. MEASUREMENTS: Antibody titers before and 1 month after vaccination by means of hemagglutinin inhibition assays for influenza types A/H1N1, A/H3N2, and B. RESULTS: A smaller proportion of the transplantation group compared with the healthy control group developed the primary outcomes of seroresponse or seroprotection for all 3 influenza types at 1 month after vaccination. The response to influenza type A/H3N2 was statistically different; the transplantation group had 69% decreased odds of developing seroresponse (95% confidence interval, 0.16 to 0.62; P = 0.001) and 78% decreased odds of developing seroprotection (95% confidence interval, 0.09 to 0.53; P = 0.001) compared with healthy controls. When participants less than 6 months from the time of transplantation were considered, this group had a significantly decreased response to the vaccine compared with healthy controls. LIMITATIONS: Decreased sample size, potential for confounders, outcome measure used is the standard but does not give information about vaccine efficacy. CONCLUSIONS: Kidney transplant recipients, especially within 6 months of transplantation, had diminished antibody response to the 2006-2007 inactivated influenza vaccine.
机译:背景:在使用较新的但常用的免疫抑制药物的肾脏移植接受者中,对灭活流感疫苗的抗体反应并未得到很好的描述。我们假设,与健康对照相比,接受他克莫司治疗的肾脏移植接受者参与者的抗体应答降低。研究设计:在2006-2007年流感季节期间,对53位肾移植受者和106位健康对照参与者进行了前瞻性队列研究。所有参与者都接受了标准的灭活流感疫苗。地点和参与者:肾脏移植接受者在一个学术医学中心和健康对照者处进行了以他克莫司为基础的治疗方案。预测:存在肾脏移植。结果:接种后1个月达到血清反应(抗体滴度增加4倍)和血清保护(抗体滴度>或= 1:32)的参与者比例。测量:接种前和接种后1个月,通过A / H1N1,A / H3N2和B型流感血凝素抑制试验的抗体效价。结果:与健康对照组相比,移植组的比例更小,主要表现为接种疫苗后1个月,所有3种流感类型均出现血清反应或血清保护作用。对A / H3N2型流感的反应有统计学差异;与健康组相比,移植组血清反应的发生几率降低了69%(95%置信区间为0.16至0.62; P = 0.001),血清保护的发生几率降低了78%(95%置信区间为0.09至0.53; P = 0.001)。控件。如果考虑从移植时间起不到6个月的参与者,则与健康对照组相比,该组对疫苗的反应显着降低。限制:减少样本量,潜在的混淆因素,使用的结果度量标准,但未提供有关疫苗功效的信息。结论:肾脏移植受者,特别是在移植的六个月内,已减少了对2006-2007年灭活流感疫苗的抗体反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号